JP2000516618A - がん性表現型を反転させるための、メラノーマ分化関連遺伝子(mda 7)の使用 - Google Patents
がん性表現型を反転させるための、メラノーマ分化関連遺伝子(mda 7)の使用Info
- Publication number
- JP2000516618A JP2000516618A JP10510102A JP51010298A JP2000516618A JP 2000516618 A JP2000516618 A JP 2000516618A JP 10510102 A JP10510102 A JP 10510102A JP 51010298 A JP51010298 A JP 51010298A JP 2000516618 A JP2000516618 A JP 2000516618A
- Authority
- JP
- Japan
- Prior art keywords
- mda
- vector
- gene
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.がん細胞のがん性表現型を反転させるための方法であって、メラノーマ分 化関連遺伝子(mda-7)を含む核酸を、前記遺伝子の発現可能な条件下で前記が ん細胞に導入することにより、前記がん細胞のがん性表現型を反転させることを 具備した方法。 2.被検者におけるがん細胞のがん性表現型を反転させるための方法であって 、メラノーマ分化関連遺伝子(mda-7)を含む核酸を、前記被検者の細胞内で前 記遺伝子の発現が可能な条件下において前記被検者のがん性細胞に導入すること により、前記がん細胞のがん性表現型を反転させることを具備した方法。 3.前記核酸がベクターを含む請求項1または2記載の方法。 4.請求項1または2記載の方法であって、前記メラノーマ分化関連遺伝子( mda-7)が、当該遺伝子の発現が調節配列の制御下にあるように調節配列に連結 している方法。 5.前記調節配列が誘導的または構成的である請求項4記載の方法。 6.前記調節配列が組織特異的調節配列である請求項4記載の方法。 7.請求項1ないし6記載の方法であって、前記核酸が、裸のDNA技術、ア デノウイルスベクター、アデノ−関連ウイルスベクター、エプスタイン−バール ウイルスベクター、ヘルペスウイルスベクター、弱毒HIVベクター、レトロウ イルスベクター、ワクシニアウイルスベクター、リポソーム、抗体で被覆したリ ポソーム、または機械的もしくは電気的手段により、前記がん細胞に導入される 方法。 8.請求項1ないし7記載の方法であって、前記がん細胞が、当該がん細胞内 に欠陥性腫瘍抑制遺伝子が存在することにより特徴付けられる方法。 9.請求項8記載の方法であって、前記腫瘍抑制遺伝子がp53、網膜芽細胞 腫(RB)またはp16ink4a遺伝子である方法。 10.請求項1ないし7記載の方法であって、前記がん細胞が、当該がん細胞 内に優性作用的がん遺伝子が存在することにより特徴付けられる方法。 11.請求項10記載の方法であって、前記優性作用的がん遺伝子が、Ha-ras 、突然変異体p53またはヒトパピローマウイルス遺伝子である方法。 12.請求項3記載の方法であって、前記ベクターが、アデノウイルスベクタ ー、アデノ−関連ウイルスベクター、エプスタイン−バールウイルスベクター、 ヘルペスウイルスベクター、弱毒HIVベクター、レトロウイルスベクターまた はワクシニアウイルスベクターである方法。 13.請求項12記載の方法であって、前記アデノウイルスベクターが、mda- 7を発現する複製欠陥性アデノウイルスベクター(名称Ad.mda-7 S)であ る方法。 14.がん細胞のがん性表現型を反転させるための方法であって、メラノーマ 分化関連遺伝子(mda-7)の遺伝子産物を前記がん性細胞に導入することにより 、前記がん細胞のがん性表現型を反転させることを具備した方法。 15.被検者におけるがん細胞のがん性表現型を反転させるための方法であっ て、メラノーマ分化関連遺伝子(mda-7)の遺伝子産物を前記被検者のがん性細 胞に導入することにより、前記がん細胞のがん性表現型を反転させることを具備 した方法。 16.請求項1ないし15記載の方法であって、前記がん細胞が、胸部、子宮 頚頸部、結腸、前立腺、鼻咽頭、肺、多形膠芽腫、リンパ腫、白血病、結合組織 または神経系の細胞である方法。 17.がん細胞のがん性表現型を反転させるために有効なメラノーマ分化関連 遺伝子(mda-7)を含む一定量の核酸と、薬学的に許容可能なキャリアとを含有 する薬学的組成物。 18.前記核酸がベクターを含む請求項17記載の薬学的組成物。 19.請求項18記載の薬学的組成物であって、前記ベクターが、アデノウイ ルスベクター、アデノ−関連ウイルスベクター、エプスタイン−バールウイルス ベクター、ヘルペスウイルスベクター、弱毒HIVベクター、レトロウイルスベ クターまたはワクシニアウイルスベクターである薬学的組成物。 20.請求項19記載の薬学的組成物であって、前記アデノウイルスベクター が、mda-7を発現する複製欠陥性アデノウイルスベクター(名称Ad.mda-7S )である薬学的組成物。 21.がん細胞のがん性表現型を反転させるために有効なメラノーマ分化関連 遺伝子(mda-7)の一定量の遺伝子産物と、薬学的に許容可能なキャリアとを含 有する薬学的組成物。 22.請求項17ないし21記載の薬学的組成物であって、前記がん細胞が、胸 部、子宮頸部、結腸、前立腺、鼻咽頭、肺、多形膠芽腫、リンパ腫、白血病、結 合組織または神経系の細胞である薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/696,573 | 1996-08-16 | ||
US08/696,573 US5710137A (en) | 1996-08-16 | 1996-08-16 | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
PCT/US1997/014548 WO1998006441A1 (en) | 1996-08-16 | 1997-08-15 | USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011221094A Division JP2012051909A (ja) | 1996-08-16 | 2011-10-05 | がん性表現型を反転させるためのメラノーマ分化関連遺伝子(mda7)の使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000516618A true JP2000516618A (ja) | 2000-12-12 |
JP4890666B2 JP4890666B2 (ja) | 2012-03-07 |
Family
ID=24797643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51010298A Expired - Fee Related JP4890666B2 (ja) | 1996-08-16 | 1997-08-15 | がん性表現型を反転させるための、メラノーマ分化関連遺伝子(mda7)の使用 |
JP2011221094A Withdrawn JP2012051909A (ja) | 1996-08-16 | 2011-10-05 | がん性表現型を反転させるためのメラノーマ分化関連遺伝子(mda7)の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011221094A Withdrawn JP2012051909A (ja) | 1996-08-16 | 2011-10-05 | がん性表現型を反転させるためのメラノーマ分化関連遺伝子(mda7)の使用 |
Country Status (15)
Country | Link |
---|---|
US (6) | US5710137A (ja) |
EP (2) | EP2251040A1 (ja) |
JP (2) | JP4890666B2 (ja) |
KR (2) | KR100528047B1 (ja) |
CN (2) | CN100363057C (ja) |
AT (1) | ATE505206T1 (ja) |
AU (1) | AU727735B2 (ja) |
BR (1) | BRPI9711137B8 (ja) |
CA (1) | CA2263750C (ja) |
DE (1) | DE69740175D1 (ja) |
DK (1) | DK0957941T3 (ja) |
ES (1) | ES2364513T3 (ja) |
NZ (1) | NZ334034A (ja) |
SI (1) | SI0957941T1 (ja) |
WO (1) | WO1998006441A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR200449370Y1 (ko) | 2010-04-26 | 2010-07-06 | 범진아이엔디(주) | 두께가 두꺼운 제품을 수축 및 기포없이 사출하는 금형 |
JP2018532810A (ja) * | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69435103D1 (de) * | 1993-10-27 | 2008-07-10 | Univ Columbia | Methode zur Bildung einer subtrahierten cDNA Bank und ihre Verwendung |
US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
US6825320B1 (en) | 1995-03-29 | 2004-11-30 | Millenium Pharmaceuticals, Inc. | FOHY03 polypeptides |
US6794185B1 (en) | 1995-03-29 | 2004-09-21 | Millennium Pharmaceuticals, Inc. | fohy030 nucleic acid molecules |
US6251597B1 (en) | 1996-03-29 | 2001-06-26 | Millennium Pharmaceuticals, Inc. | Methods for detecting fohy030 |
US6312909B1 (en) | 1996-03-29 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis prevention and treatment of tumor progression |
US5710137A (en) * | 1996-08-16 | 1998-01-20 | The Trustees Of Columbia University In The City Of New York | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
AU2469799A (en) * | 1998-01-26 | 1999-08-09 | Genquest Inc. | Differentiation-associated sequences and methods of use therefor |
US6413717B1 (en) | 1998-03-18 | 2002-07-02 | Corixa Corporation | Methods for indentifying anti-cancer agents |
WO1999060124A2 (en) * | 1998-05-15 | 1999-11-25 | Fei Huang | Differentiation-associated sequences and methods of use therefor |
WO2000046391A2 (en) * | 1999-02-02 | 2000-08-10 | The Trustees Of Columbia University In The City Of New York | Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
US6841362B1 (en) | 2000-02-29 | 2005-01-11 | The Trustees Of Columbia University In The City Of New York | Melanoma differentiation associated gene-7 promoter and uses thereof |
WO2002033975A2 (en) * | 2000-10-15 | 2002-04-25 | Sonicblue Incorporated | Method and system for dynamic ad placement |
CA2429769C (en) * | 2000-12-07 | 2016-04-26 | Board Of Regents, The University Of Texas System | Methods of treatment involving human mda-7 |
GB0109515D0 (en) * | 2001-04-17 | 2001-06-06 | Neg Micon As | A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
US20030082140A1 (en) * | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
AU2003228267A1 (en) * | 2002-03-05 | 2003-09-22 | Board Of Regents, The University Of Texas System | Methods of enhancing immune induction involving mda-7 |
EP1578196A4 (en) * | 2002-12-23 | 2006-04-12 | Univ Columbia | MDA-7 AND FREE RADICALS USED IN THE TREATMENT OF CANCER |
AU2004218407A1 (en) * | 2003-03-03 | 2004-09-16 | Board Of Regents, The University Of Texas System | Methods and compositions involving MDA-7 |
US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
ATE420160T1 (de) | 2003-06-18 | 2009-01-15 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
CA2548220A1 (en) * | 2003-12-01 | 2005-09-09 | Introgen Therapeutics, Inc. | Use of mda-7 to inhibit infection by pathogenic organisms |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
US20080026410A1 (en) * | 2004-12-02 | 2008-01-31 | Antonia Vlahou | Biomarkers for Bladder Cancer |
CN101166539B (zh) * | 2005-02-08 | 2012-01-04 | 得克萨斯大学体系董事会 | 用于治疗癌症的涉及mda-7的组合物和方法 |
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
WO2008156655A2 (en) * | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
US10189773B2 (en) | 2010-05-07 | 2019-01-29 | Medicus Biosciences, Llc | In-vivo gelling pharmaceutical pre-formulation |
CN101935347B (zh) * | 2010-07-27 | 2014-11-05 | 郑骏年 | mda-7/IL-24去泛素化突变体 |
US10111985B2 (en) | 2011-08-10 | 2018-10-30 | Medicus Biosciences, Llc | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
US11083821B2 (en) | 2011-08-10 | 2021-08-10 | C.P. Medical Corporation | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
US10117885B2 (en) | 2011-08-11 | 2018-11-06 | Allergy Research Group, Llc | Chewable lipid supplements for treating pain and fibromyalgia |
AU2013259166B2 (en) | 2012-05-11 | 2016-03-10 | Theragenics Corporation | Biocompatible hydrogel treatments for retinal detachment |
AU2014236385B2 (en) | 2013-03-14 | 2019-01-24 | Theragenics Corporation | Biocompatible hydrogel polymer matrix for delivery of cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011986A1 (en) * | 1993-10-27 | 1995-05-04 | The Trustees Of Columbia University In The City Of New York | METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5643761A (en) * | 1993-10-27 | 1997-07-01 | The Trustees Of Columbia University In The City Of New York | Method for generating a subtracted cDNA library and uses of the generated library |
US5710137A (en) * | 1996-08-16 | 1998-01-20 | The Trustees Of Columbia University In The City Of New York | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
US6190909B1 (en) * | 1997-04-17 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | TH2-specific gene |
US6440741B2 (en) | 1999-03-15 | 2002-08-27 | The Trustees Of Columbia University In The City Of New York | Expression vector for consistent cellular expression of the tet on repressor in multiple cell types |
WO2001005437A2 (en) | 1999-07-15 | 2001-01-25 | Introgen Therapeutics, Inc. | Methods for treatment of hyperproliferative diseases using human mda-7 |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
-
1996
- 1996-08-16 US US08/696,573 patent/US5710137A/en not_active Expired - Lifetime
-
1997
- 1997-08-15 AU AU42319/97A patent/AU727735B2/en not_active Expired
- 1997-08-15 BR BRPI9711137A patent/BRPI9711137B8/pt not_active IP Right Cessation
- 1997-08-15 KR KR10-1999-7002342A patent/KR100528047B1/ko not_active IP Right Cessation
- 1997-08-15 WO PCT/US1997/014548 patent/WO1998006441A1/en active IP Right Grant
- 1997-08-15 ES ES97940569T patent/ES2364513T3/es not_active Expired - Lifetime
- 1997-08-15 NZ NZ334034A patent/NZ334034A/xx not_active IP Right Cessation
- 1997-08-15 DK DK97940569.3T patent/DK0957941T3/da active
- 1997-08-15 CN CNB2004100544774A patent/CN100363057C/zh not_active Expired - Lifetime
- 1997-08-15 JP JP51010298A patent/JP4890666B2/ja not_active Expired - Fee Related
- 1997-08-15 EP EP10173743A patent/EP2251040A1/en not_active Withdrawn
- 1997-08-15 SI SI9730796T patent/SI0957941T1/sl unknown
- 1997-08-15 CA CA002263750A patent/CA2263750C/en not_active Expired - Lifetime
- 1997-08-15 DE DE69740175T patent/DE69740175D1/de not_active Expired - Lifetime
- 1997-08-15 CN CNB971979146A patent/CN1166409C/zh not_active Expired - Lifetime
- 1997-08-15 EP EP97940569A patent/EP0957941B1/en not_active Expired - Lifetime
- 1997-08-15 AT AT97940569T patent/ATE505206T1/de active
- 1997-08-15 KR KR1020057004518A patent/KR100574049B1/ko not_active IP Right Cessation
-
1999
- 1999-02-16 US US09/251,124 patent/US6355622B1/en not_active Expired - Lifetime
-
2001
- 2001-11-21 US US09/991,452 patent/US6855686B2/en not_active Expired - Fee Related
-
2005
- 2005-01-31 US US11/048,543 patent/US7291605B2/en not_active Expired - Fee Related
-
2007
- 2007-11-06 US US11/935,816 patent/US7579330B2/en not_active Expired - Fee Related
-
2009
- 2009-08-24 US US12/546,573 patent/US20100189680A1/en not_active Abandoned
-
2011
- 2011-10-05 JP JP2011221094A patent/JP2012051909A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011986A1 (en) * | 1993-10-27 | 1995-05-04 | The Trustees Of Columbia University In The City Of New York | METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR200449370Y1 (ko) | 2010-04-26 | 2010-07-06 | 범진아이엔디(주) | 두께가 두꺼운 제품을 수축 및 기포없이 사출하는 금형 |
JP2018532810A (ja) * | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4890666B2 (ja) | がん性表現型を反転させるための、メラノーマ分化関連遺伝子(mda7)の使用 | |
Niu et al. | BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells | |
Turnell et al. | The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status | |
Sers et al. | Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors | |
Jiang et al. | The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. | |
Qu et al. | The transcriptional corepressor NAB2 inhibits NGF-induced differentiation of PC12 cells | |
JP2001508290A (ja) | 新形成の治療及び予防のための細胞変性ウイルス | |
Wang et al. | Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma | |
Michalovitz et al. | Overproduction of protein p53 contributes to simian virus 40-mediated transformation | |
Rancourt et al. | Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy | |
US20060140959A1 (en) | Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof | |
Inoue et al. | Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6 | |
Li et al. | The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1 | |
Shimakage et al. | Detection of Epstein–Barr virus-determined nuclear antigen-2 mRNA by in situ hybridization | |
Chuang et al. | The Epstein–Barr virus nuclear antigen‐1 may act as a transforming suppressor of the HER2/neu oncogene | |
Foley et al. | Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforms of p53 | |
Galloway et al. | Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes | |
Liang et al. | Transcription of Epstein–Barr Virus-Encoded Nuclear Antigen 1 Promoter Qp Is Repressed by Transforming Growth Factor-β via Smad4 Binding Element in Human BL Cells | |
EP1151094A1 (en) | Cervical cancer treatment | |
DEB et al. | Transcriptional antagonism between p53 and sv40 T-antigen | |
Martel-Renoir et al. | Dimerization of the Epstein-Barr virus ZEBRA protein in the yeast two-hybrid system. Comparison of a ZEBRA variant with the B95-8 form | |
Maraldi et al. | Genetic alterations at the nuclear localization signal of the RB2/p130 gene occur in lymphoid tumor but not in osteosarcoma cell lines | |
MXPA99001582A (en) | USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE | |
Sauter | Alterations in genes regulating the G1 checkpoint are important in squamous cell carcinogenesis | |
KUROKAWA et al. | Immunohistochemical analysis of expression of tumor suppressor gene p53 protein in oral squamous cell carcinoma Correlation wit hhistological malignancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080718 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081017 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090430 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100317 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100422 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100506 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100524 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110705 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111005 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111215 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |